首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1734254

甲状旁腺功能低下症市场-全球与区域分析-分析与预测（2025-2035）

Hypoparathyroidism Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

出版日期: 2025年05月28日 | 出版商:

BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

简介目录图表

全球甲状旁腺功能低下症市场目前正处于其生命週期的成长阶段。

人们对疾病的认识不断提高以及诊断技术的进步导致市场早期诊断和治疗的增加。包括新型副甲状腺素疗法在内的新治疗方法的开发正在扩大治疗甲状旁腺功能低下症的治疗选择，进一步推动市场成长。此外，人们对罕见疾病和个人化医疗的日益关注，加上有利的监管支持，正在刺激对研发的投资，从而带来创新治疗方法的推出。

随着新兴市场医疗保健服务的改善和治疗选择的日益广泛，预计市场将继续扩大。然而，治疗费用上涨和某些地区认知度低等挑战可能会影响成长速度。总体而言，由于治疗方法的不断进步和全球影响力的不断扩大，全球甲状旁腺功能低下症市场预计将持续成长。

影响

预计在 2025-2035 年预测期内，对甲状旁腺功能低下症治疗的需求不断增加将支持全球甲状旁腺功能低下症市场的成长。
由于标靶治疗药物的开发、认识和诊断的提高以及临床管道的不断扩大，全球甲状旁腺功能低下症市场预计将显着增长。

近期动态

监管活动：2025 年 2 月，Specialised Therapeutics 的 YORVIPATH核准用于治疗成人慢性甲状旁腺功能低下症。
监管行动 2024 年 8 月，FDA核准了一种每日一次的副甲状腺素前驱药物，用于治疗成人甲状旁腺功能低下症。
伙伴关係：2024 年 7 月，製药科学部门 Pendopharm 与 scendis Pharma 签署了独家分销协议，将治疗甲状旁腺功能低下症的药物 TransCon PTH（paropegteriparatide）引入加拿大市场。

需求－驱动因素与限制因素

驱动程式

甲状旁腺功能低下症功能低下症盛行率不断上升
诊断技术的认识提升与进步

限制因素

医疗费用高昂

产品/创新策略：全球甲状旁腺功能低下症市场的创新以增强患者护理的治疗方案的进步为中心。市场的主要参与企业如 Specialised Therapeutics 和 Ascendis Pharma 都参与开发甲状旁腺功能低下症的治疗方法。

竞争策略：领先的市场参与者不断透过创新治疗方法更新产品系列以保持竞争力。它对主要参与者进行了详细的竞争基准化分析，并提供了这些公司在产品平臺和创新方面的比较情况的见解。透过这种基准测试，读者可以清楚地了解市场格局和主要企业的地位。此外，包括伙伴关係、协议和联盟在内的综合竞争策略可协助读者发现市场中尚未开发的商机。

主要市场参与企业及竞争格局

公司简介是根据从主要专家收集的资讯以及透过分析公司覆盖范围、产品系列和市场渗透率来选择的。

本报告研究了全球甲状旁腺功能低下症市场，并概述了市场以及区域趋势和公司概况。

The global hypoparathyroidism market is currently in the growth stage of its lifecycle. With increasing awareness of the condition and advancements in diagnostic technologies, the market is witnessing a rise in early diagnosis and treatment initiation. The development of new therapies, including novel parathyroid hormone treatments, has expanded the treatment options available for managing hypoparathyroidism, further fueling market growth. Additionally, the growing focus on rare diseases and personalized medicine, coupled with favorable regulatory support, has spurred investment in research and development, leading to the introduction of innovative therapies.

As healthcare access improves in emerging markets and treatment options become more widely available, the market is expected to continue its expansion. However, challenges such as high treatment costs and limited awareness in certain regions may impact the pace of growth. Overall, the global hypoparathyroidism market is positioned for continued growth with increasing therapeutic advancements and expanding global reach.

Impact

Increasing demand for hypoparathyroidism therapies is anticipated to support the growth of the global hypoparathyroidism market during the forecast period 2025-2035.
The global hypoparathyroidism market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline.

Recent Developments

Regulatory Activities: In February 2025, Therapeutic Goods Administration approved Specialised Therapeutics' YORVIPATH for the treatment of chronic hypoparathyroidism in adults.
Regulatory Activities: In August 2024, the FDA approved a once-daily parathyroid hormone prodrug for the treatment of adults with hypoparathyroidism.
Partnerships: In July 2024, Pharmascience unit Pendopharm entered into an exclusive distribution agreement with Ascendis Pharma to bring the hypoparathyroidism treatment TransCon PTH (palopegteriparatide) to the Canadian market.

Demand - Drivers and Limitations

Drivers:

Increasing Prevalence of Hypoparathyroidism
Rising Awareness and Advancements in Diagnostic Technologies

Limitations:

High Treatment Costs

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Innovations in the global hypoparathyroidism market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Specialised Therapeutics and Ascendis Pharma, have been involved in the development of therapies for hypoparathyroidism.

Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.

Some of the prominent names established in this market are:

Ascendis Pharma
AstraZeneca
Bridgebio
Entera Bio Ltd.
MBX Biosciences, Inc.
Specialised Therapeutics
Visen Pharmaceuticals (Shanghai) Co., Ltd.

Scope of Study

1. Global Hypoparathyroidism Market Overview

1.1 Industry Outlook
- 1.1.1 Market Overview and Ecosystem
- 1.1.2 Market Trend
- 1.1.3 Epidemiological Analysis of Hypoparathyroidism
  - 1.1.3.1 By Region
    - 1.1.3.1.1 U.S.
    - 1.1.3.1.2 EU5
    - 1.1.3.1.3 Rest-of-the-World
- 1.1.4 Clinical Trials
  - 1.1.4.1 By Phase
  - 1.1.4.2 By Sponsor Type
- 1.1.5 Regulatory Landscape / Compliance
  - 1.1.5.1 Legal Requirement and Framework in the U.S.
  - 1.1.5.2 Legal Requirement and Framework in the E.U.
  - 1.1.5.3 Legal Requirement and Framework in Japan
  - 1.1.5.4 Legal Requirement and Framework in Rest-of-the-World
1.2 Market Dynamics
- 1.2.1 Impact Analysis
- 1.2.2 Market Drivers
- 1.2.3 Market Restraints
- 1.2.4 Market Opportunities

2. Global Hypoparathyroidism Market, By Region, $Million, 2023-2035

2.1 U.S.
- 2.1.1 Market Dynamics
- 2.1.2 Market Size and Forecast
2.2 Europe
- 2.2.1 Market Dynamics
- 2.2.2 Market Size and Forecast
  - 2.2.2.1 Europe Hypoparathyroidism Market (by Country)
    - 2.2.2.1.1 U.K.
    - 2.2.2.1.2 Germany
    - 2.2.2.1.3 France
    - 2.2.2.1.4 Italy
    - 2.2.2.1.5 Spain
2.3 Rest-of-the-World
- 2.3.1 Market Dynamics
- 2.3.2 Market Size and Forecast

3. Global Hypoparathyroidism Market - Competitive Benchmarking and Company Profiles

3.1 Competitive Landscape
- 3.1.1 Key Strategies and Developments by Company
  - 3.1.1.1 Funding Activities
  - 3.1.1.2 Mergers and Acquisitions
  - 3.1.1.3 Regulatory Approvals
  - 3.1.1.4 Partnerships, Collaborations and Business Expansions
- 3.1.2 Key Developments Analysis
3.2 Company Profiles
- 3.2.1 Ascendis Pharma
  - 3.2.1.1 Company Overview
  - 3.2.1.2 Product Portfolio
  - 3.2.1.3 Target Customers/End Users
  - 3.2.1.4 Analyst View
- 3.2.2 AstraZeneca
  - 3.2.2.1 Company Overview
  - 3.2.2.2 Product Portfolio
  - 3.2.2.3 Target Customers/End Users
  - 3.2.2.4 Analyst View
- 3.2.3 Bridgebio
  - 3.2.3.1 Company Overview
  - 3.2.3.2 Product Portfolio
  - 3.2.3.3 Target Customers/End Users
  - 3.2.3.4 Analyst View
- 3.2.4 MBX Biosciences, Inc.
  - 3.2.4.1 Company Overview
  - 3.2.4.2 Product Portfolio
  - 3.2.4.3 Target Customers/End Users
  - 3.2.4.4 Analyst View
- 3.2.5 Entera Bio Ltd.
  - 3.2.5.1 Company Overview
  - 3.2.5.2 Product Portfolio
  - 3.2.5.3 Target Customers/End Users
  - 3.2.5.4 Analyst View
- 3.2.6 Specialised Therapeutics
  - 3.2.6.1 Company Overview
  - 3.2.6.2 Product Portfolio
  - 3.2.6.3 Target Customers/End Users
  - 3.2.6.4 Analyst View
- 3.2.7 Visen Pharmaceuticals (Shanghai) Co., Ltd.
  - 3.2.7.1 Company Overview
  - 3.2.7.2 Product Portfolio
  - 3.2.7.3 Target Customers/End Users
  - 3.2.7.4 Analyst View

4. Research Methodology

简介目录图表

List of Figures

Figure: Global Hypoparathyroidism Market, Market Overview
Figure: Global Hypoparathyroidism Market, Epidemiological Analysis, U.S.
Figure: Global Hypoparathyroidism Market Coverage
Figure: Global Hypoparathyroidism Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Hypoparathyroidism Market, Competitive Landscape, January 2022-April 2025